Aquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 25,000 Shares of Company Stock

Key Points

• CEO Daniel Barber sold 25,000 AQST shares at an average price of $4.22, generating $105,500. The sale, conducted under a Rule 10b5-1 plan, reduced his holdings by 3.83% to 627,317 shares.
• Aquestive shares fell to $3.83, while the company reported a quarterly loss of $0.18 per share—worse than the $0.10 consensus estimate—despite revenue of $13.82 million exceeding forecasts.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an $8.60 average price target; institutional investors own 32.45% of the company.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) CEO Daniel Barber sold 25,000 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the transaction, the chief executive officer owned 627,317 shares of the company's stock, valued at approximately $2,647,277.74. This trade represents a 3.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

• On Tuesday, September 15th, Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.82, for a total value of $120,500.00.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded down $0.23 on Friday, hitting $3.83. The company's stock had a trading volume of 3,672,013 shares, compared to its average volume of 2,966,138. Aquestive Therapeutics, Inc. has a 12 month low of $2.93 and a 12 month high of $7.55. The company has a market capitalization of $481.33 million, a price-to-earnings ratio of -5.90 and a beta of 1.49. The stock's 50-day moving average is $4.75 and its two-hundred day moving average is $4.35.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. Equities analysts expect that Aquestive Therapeutics, Inc. will post -0.50 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Blue Owl Capital Holdings LP acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth $3,923,000. Latash Investments LLC acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth $1,011,000. Wasatch Advisors LP raised its position in shares of Aquestive Therapeutics by 57.8% during the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company's stock worth $5,765,000 after purchasing an additional 507,527 shares during the period. BlackRock Inc. purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at $33,569,000. Finally, Walleye Capital LLC purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at $1,175,000. Institutional investors own 32.45% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AQST. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 target price on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Wall Street Zen upgraded shares of Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.60.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company's oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.

Aquestive's commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.